ELV

Elevance Health
D

ELV

Arincen57/100B

If you had invested in Elevance Health ago, it would be worth $3,691 today, against $4,096 in SPY and $6,368 in QQQ.

ArincenArincen ScoreBeta

57/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability2

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Elevance Health key facts

Style
Value stock · 6.7/10Growth 4.0 · Value 6.7 · Dividend 5.2
Day range
426.82 – 433.23
52-week range
274.84 – 450.69
Market capitalization
92.35B USD
P/E
18.20
PEG ratio
1.61
EPS
23.48
Div Yield
1.61%
EPS growth forecast (FY2026)
-3.7%
Volume
979
Beta
0.71
ESG score
55.4/100Environment 55 · Social 56 · Governance 55
Sector
Healthcare
Industry
Medical - Healthcare Plans
CEO
Gail Koziara Boudreaux
Employees
97K
IPO date
30 Oct 2001

Elevance Health earnings

Next earnings · Q4 FY2026
EPS estimate
2.08 USD
Revenue estimate
49.38B USD
Last quarter · Q3 FY2026
EPS6.99Beat +48.4%Revenue50.44BBeat +2.4%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20276.15——-11.96%51.54B——+2.18%
Q2 FY20278.18——+9.75%51.16B——+2.67%
Q1 FY202712.41——-1.36%50.53B——+2.10%
Q4 FY20262.08——-37.54%49.38B——+0.13%
Q3 FY20264.716.99+48.41%+15.92%49.28B50.44B+2.35%+0.70%
Q2 FY20266.217.45+19.97%-15.72%48.88B49.83B+1.94%+0.82%
Q1 FY202610.8212.58+16.27%+5.10%48.20B49.49B+2.68%+1.49%
Q4 FY20253.103.33+7.42%-13.28%49.84B49.31B-1.07%+8.51%
Q3 FY20254.936.03+22.31%-27.96%49.38B50.09B+1.43%+10.95%
Q2 FY20258.918.84-0.79%-12.65%48.19B49.42B+2.55%+13.23%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Elevance Health analyst forecast

12-month price target
466.69 USD
+9.18%

Analysts' 1-year price targets range from 395.00 to 523.00, with an average of 466.69.

Past year
1-year forecast
Strong sellStrong buy
Buy
19 ratings
Buy
14
Hold
5
Sell
0

12-month price target

Highest target523.00
Average target466.69
Lowest target395.00
Current price427.45

Elevance Health valuation

Price to earnings ratio (TTM)
18.20
Forward P/E (FY2026)
14.71
Price to sales (TTM)
0.46
Price to book
2.07
EV / EBITDA (TTM)
9.61

Capital structure

Market capitalization
92.35B USD
+
Total debt
30.76B USD
−
Cash and short-term investments
37.85B USD
=
Enterprise value
85.26B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)12.35————
FY2027 (est.)14.1312.35———
FY2026 (est.)14.7114.13———
Now (TTM)18.2014.210.462.079.61
FY202513.9212.060.391.7710.51
FY202414.2915.520.492.0810.52
FY202318.5815.520.642.8012.40
FY202220.8915.520.793.4013.98
FY202118.3615.970.823.1313.27

Elevance Health against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: CVS Health, Cigna, Humana, Centene, UnitedHealth Group, and Molina Healthcare, the US Medical - Healthcare Plans companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median18.2
    11.221.4
  • Gross marginBelow its median25.6%
    25.5%27.9%
    Against its peers: 1 of 7Peers' median 13.0%
  • Operating marginLowest in 5 years4.1%
    4.1%6.5%
    Against its peers: 2 of 7Peers' median 2.2%
  • Net marginLowest in 5 years2.8%
    2.8%4.4%
    Against its peers: 1 of 7Peers' median 1.0%
  • Return on equityLowest in 5 years12.9%
    12.9%16.9%
    Against its peers: 2 of 7Peers' median 9.2%
  • Free cash flow marginLowest in 5 years1.6%
    1.6%5.2%
    Against its peers: 5 of 7Peers' median 2.1%
  • Revenue growthAt its median12.6%
    3.2%13.8%
    Against its peers: 2 of 7Peers' median 11.5%
  • EPS growthLowest in 5 years-2.2%
    -2.2%37.5%
    Against its peers: 3 of 7Peers' median -35.5%
  • Debt to EBITDAHighest in 5 years3.44×
    2.48×3.44×
    Against its peers: 3 of 6Peers' median 4.05×
  • Current ratioHighest in 5 years1.24
    0.941.24
    Against its peers: 3 of 7Peers' median 0.85

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Elevance Health growth and profitability

Revenue (TTM)
201.83B USD
Net income (TTM)
5.14B USD
Gross margin
36.55%
Operating margin
3.69%
Net margin
2.55%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY2025199.13B+12.62%5.66B-5.32%25.56%4.07%2.84%9.66B-7.86%
FY2024176.81B+3.19%5.98B-0.12%27.85%5.03%3.38%10.48B-0.08%
FY2023171.34B+9.42%5.99B+1.58%27.44%5.10%3.49%10.49B+3.59%
FY2022156.60B+12.95%5.89B-3.44%25.51%5.40%3.76%10.13B+1.01%
FY2021138.64B+13.76%6.10B+33.51%25.96%6.45%4.40%10.03B+22.61%

Elevance Health revenue breakdown

By product

FY2025
Health Benefits: 70.0%Carelon Services: 30.0%70.0%Health Benefits30.0%Carelon Services
SegmentRevenueShare of revenueChange on the year
Health Benefits167.09B70.0%+11.2%
Carelon Services71.72B30.0%+33.0%

How Elevance Health makes its money

Revenue199.13B 100.0%
Cost of revenue148.22B 74.4%
Gross profit50.90B 25.6%
Other operating expenses42.79B 21.5%
Operating income8.11B 4.1%
Tax1.05B 0.5%
Other expense1.40B 0.7%
Net income5.66B 2.8%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Elevance Health dividends

Annual dividend
6.88 USD
Dividend yield (indicated)
1.61%
Payout ratio
36.58%
Years of dividend growth
15
Frequency
Quarterly
Next payment
1.72 USD
Next ex-dividend date
4 Dec 2026
Next payment date
18 Dec 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share6.846.525.925.124.523.803.203.002.702.60

Elevance Health financial health

Cash and short-term investments
37.85B USD
Total debt
30.76B USD
Net cash
7.09B USD
Free cash flow (TTM)
6.51B USD
Current ratio
1.47
Debt to equity
0.69
Piotroski score
7 / 9
Altman Z-score
3.06

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20259.49B33.24B3.17B
FY20248.29B32.70B4.55B
FY20236.53B26.65B6.77B
FY20227.39B25.80B7.25B
FY20214.88B24.89B7.28B

Elevance Health ownership

Institutions
92.37%
Institutional holders
1,681 (+154)
Free float
99.77%

Who owns the shares

Institutions 92.4% Others 7.6%
As of 30 Jun 2026

Shares free to trade

Free float 215.57M shares ·99.8% Closely held 486.24K shares ·0.2%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 20260142.63K16.05K
Q3 2026303.73K493.00
Q2 2026037.16K3.58K
Q1 202612258.68K19.27K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025221.80M221.80M-4.77%
FY2024232.87M232.90M-1.90%
FY2023233.07M237.40M-2.22%
FY2022240.00M242.80M-1.62%
FY2021243.80M246.80M-2.95%

Source: Financial Modeling Prep

News

Title: Elevance Health

Sector: Healthcare
Industry: Medical - Healthcare Plans
Elevance Health Inc. is a healthcare company incorporated in the US. Its main services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Its stated goal is to improve lives and communities while making healthcare simpler. It is a dominant player in medical plans and based on its 2021 revenues, was ranked 20th on the 2022 Fortune 500. The company has changed names along the way since its inception in 1944. It is headquartered in Indianapolis, Indiana. Prior to June 2022, Elevance Health was named Anthem, Inc.

Common questions about Elevance Health stock